KINAXO Launches Enhanced KinaTor(TM) Cellular Profiling Service

Martinsried, Germany, 8th October 2007. KINAXO Biotechnologies today announced that it has added quantitative analysis to its KinaTor(TM) chemical proteomics platform tailored for the cellular profiling of kinase inhibitors. The enhanced KinaTor(TM) Cellular Profiling Service enables KINAXO's pharmaceutical and biotechnology clients to make more informed decisions on which drug candidates to progress into advanced pre-clinical development. The KinaTor(TM) Cellular Profiling Service platform may be employed in a number of further applications including target identification, drug reprofiling and drug rescue. Commenting on the launch of the new service Dr Andreas Jenne KINAXO's CEO said: "KINAXO is delighted to announce this significant development in the capabilities of our successful KinaTor(TM) platform. We look forward to putting the enhanced KinaTor(TM) Cellular Profiling Service to work for our existing and future clients.'" KINAXO's quantitative KinaTor(TM) Cellular Profiling Service utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify not only the drug candidate's native molecular targets from cellular samples but also the affinities of these interactions. This data provides a valuable insight into the drug candidate's in vivo molecular target profile. The technology was developed by Dr Henrik Daub and Professor Axel Ullrich of the Max Planck Institute of Biochemistry in Martinsried and has been exclusively licensed by its technology transfer organization Max Planck Innovation to KINAXO Biotechnologies. Commenting on the new service, Dr Klaus Godl KINAXO's CSO said; "It is critically important that all biological interactions of a kinase inhibitor are evaluated, not just those with a subset of recombinant kinases. The new service will enable not only the identification of drug candidate interactions with proteins derived from real cellular samples but importantly also their affinities thus supporting more informed lead candidate selection." About KINAXO KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drug leads. Amongst others KINAXO has ongoing collaborations with UCB Pharma and Johnson & Johnson. KINAXO offers its clients a comprehensive chemical-proteomics platform - known as KinaTor(TM) - that identifies and characterizes the interaction of small molecule inhibitors with their cellular protein targets. Tailored to protein kinases, the KinaTor(TM) technology supports more informed lead candidate selection. Licensing agreements with GPC Biotech AG and the Max Planck Society provides KINAXO Biotechnologies GmbH with exclusive worldwide rights to use the KinaTor(TM) technology in contract research activities. Contact Dr. Andreas Jenne, CEO, KINAXO Biotechnologies GmbH, Am Klopferspitz 19a, 82152 Martinsried, Germany,, +498946133630,